natgillin/translations-raw huggingface dataset:
IDNT-studiet (Irbesartan Diabetic Nephropathy Trial) har vist, at irbesartan nedsætter progression af nyresygdom hos patienter med kronisk nyreinsufficiens og klinisk proteinuri. 
The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria.
Der er set en begrænset akkumulering af irbesartan (< 20 %) i plasma efter gentagne doseringer, en gang dagligt. 
Limited accumulation of irbesartan (< 20 %) is observed in plasma upon repeated once-daily dosing.
• Graviditet i 2. og 3. trimester (se pkt. 
• Second and third trimesters of pregnancy (see section 4.4 and 4.6).
Hos diabetiske, hypertensive patienter med mikroalbuminuri og normal nyrefunktion sås hyperkaliæmi (≥ 5,5 mEq/l) hos 29,4 % af patienterne i irbesartan 300 mg-gruppen og 22 % af patienterne i placebogruppen. 
In diabetic hypertensive patients with microalbuminuria and normal renal function, hyperkalaemia (≥ 5.5 mEq/L) occurred in 29.4 % of the patients in the irbesartan 300 mg group and 22 % of the patients in the placebo group.
I dyrestudier med irbesartan sås forbigående toksisk effekt (øget nyrebækken-kavitation, hydroureter eller subkutant ødem) hos rottefostre. 
Animal studies with irbesartan showed transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth.
Det er kendt, at eksponering for behandling med AIIRA'er under andet og tredje trimester kan inducere human føtotoksicitet (nedsat nyrefunktion, oligohydramnios, hæmning af kraniets knogledannelse) og neonatal toksicitet (nyresvigt, hypotension, hyperkaliæmi) (se pkt. 
Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).
En laverestartdosis (75 mg) bør overvejes hos patienter i hæmodialyse (se pkt. 
A lower starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).
Det er også indiceret til behandling af nyresygdom hos voksne patienter med hypertension og type 2 diabetes mellitus, som del af et antihypertensivt lægemiddelregime (se pkt. 
It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).
Hypertensive patienter med type 2 diabetes og nyresygdom I en analyse udført i en undersøgelse med patienter med fremskreden nyresygdom var effekten af irbesartan på nyrer og kardiovaskulære hændelser ikke den samme i alle sub-grupper. 
Hypertensive patients with type 2 diabetes and renal disease The effects of irbesartan both on renal and cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study with patients with advanced renal disease.
• hvis du lider af nyreproblemer. 
If you suffer from kidney problems
Da der ikke foreligger oplysninger om anvendelse af irbesartan under amning, frarådes brugen af irbesartan, og andre behandlingsregimer med en mere veletableret sikkerhedsprofil for anvendelse under amning bør foretrækkes. 
Because no information is available regarding the use of irbersartan during breast-feeding, irbesartan is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
• hvis du samtidig tager et af følgende lægemidler til behandling af for højt blodtryk: - en ACE-hæmmer (f.eks. enalapril, lisinopril, ramipril), især hvis du har nyrerproblemer i forbindelse med sukkersyge - aliskiren 
if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems - aliskiren
• Ikke almindelig (kan kan forekomme hos op til 1 ud af 100 patienter): hurtig hjerterytme, rødme, hoste, diarré, fordøjelsesbesvær/halsbrand, seksuelle problemer, brystsmerter. 
Uncommon (may affect up to 1 in 100 people): heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (problems with sexual performance), chest pain.
• Almindelig (kan forekomme hos op til 1 ud af 10 patienter): svimmelhed, kvalme/opkastning, træthed og blodprøver, der viser en forhøjet mængde af et enzym, der måler muskel- og hjertefunktionen (kreatinin-kinase-enzym).Der er hos patienter med forhøjet blodtryk og type 2 
Common (may affect up to 1in 10 people): dizziness, feeling sick/vomiting, fatigue and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase enzyme).
Irbesartan Teva mindsker faldende nyrefunktionen hos patienter med forhøjet blodtryk og type 2 diabetes (sukkersyge). 
Irbesartan Teva slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.
Spørg lægen eller apotekspersonalet hvis der er noget, du er i tvivl om. 
Check with your doctor or pharmacist if you are not sure.
• Patienter med højt blodtryk og type 2-diabetes med nyresygdom 
Patients with high blood pressure and type 2 diabetes with kidney disease
Blandt diabetiske, hypertensive patienter med kronisk nyreinsufficiens og udtalt proteinuri sås hyperkaliæmi (≥ 5,5 mEq/l) hos 46,3 % af patienterne i irbesartangruppen og 26,3 % af patienterne i placebogruppen. 
In diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria, hyperkalaemia (≥ 5.5 mEq/L) occurred in 46.3 % of the patients in the irbesartan group and 26.3 % of the patients in the placebo group.
diabetes med nyresygdom også indberettet svimmelhed, når man rejser sig op fra liggende ellersiddende stilling, lavt blodtryk når man rejser sig op fra liggende eller siddende stilling, led- og muskelsmerter og en nedsat mængde protein i de røde blodlegemer (hæmoglobin). 
dizziness when getting up from lying or sitting position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (haemoglobin) were also reported.
På trods af dette er irbesartan uden risiko blevet administreret sammen med andre antihypertensive lægemidler som beta-blokkere, langtidsvirkende calciumkanalblokkere samt diuretika af thiazidtypen. 
Other antihypertensive agents may increase the hypotensive effects of irbesartan; however irbesartan has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Yderligere information om irbesartan-interaktioner Irbesartans farmakokinetik er i kliniske forsøg ikke påvirket af hydrochlorthiazid. 
In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
IRMA 2 var et placebo-kontrolleret dobbelt blindt morbiditetsstudie med 590 patienter med type 2 diabetes, mikroalbuminuri (30-300 mg/dag) og normal nyrefunktion (serumkreatinin ≤ 1,5 mg/dl hos mænd og < 1,1 mg/dl hos kvinder). 
590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and < 1.1 mg/dl in females).
Irbesartan Teva 75 mg filmovertrukne tabletter Irbesartan Teva 150 mg filmovertrukne tabletter Irbesartan Teva 300 mg filmovertrukne tabletter 
Irbesartan Teva 75 mg film-coated tablets Irbesartan Teva 150 mg film-coated tablets Irbesartan Teva 300 mg film-coated tablets
• hvis du har sukkersyge eller nedsat nyrefunktion, og du også tager et blodtrykssænkende lægemiddel, der indeholder aliskiren 
if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren
Hvis du bliver svimmel eller træt skal du kontakte lægen, inden du kører bil eller betjener maskiner. 
If you experience these, talk to your doctor before attempting to drive or use machines.
Pakningsstørrelser og yderligere oplysninger Irbesartan Teva indeholder: 
Contents of the pack and other information What Irbesartan Teva contains
Der var dog færre patienter i irbesartan der fik 300 mg (5,2 %) som nåede endepunktet, klinisk proteinuri, sammenlignet med placebo-gruppen (14,9 %) og irbesartangruppen der fik 150 mg (9,7 %), hvilket viste en relativ risikoreduktion på 70 % versus placebo (p = 0,0004) ved den højere dosis. 
While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2 %) than in the placebo (14.9 %) or in the irbesartan 150 mg group (9.7 %) reached the endpoint of overt proteinuria, demonstrating a 70 % relative risk reduction versus placebo (p = 0.0004) for the higher dose.
Doser på 150-300 mg, 1 gang i døgnet, giver en sænkning af det liggende eller siddende blodtryk i minimumpunktet (dvs. 24 timer efter dosering), som i gennemsnit er 8-13/5-8 mmHg (systolisk/diastolisk) større end ved placebo-behandling. 
The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.
Den anden side af tabletten er præget med tallet "7466". 
The other side of the tablet debossed with number “7466”.
Som det er tilfældet med ACE-hæmmere, kan samtidig anvendelse af angiotensin-II-antagonister og NSAID medføre øget risiko for forværring af nyrefunktionen herunder muligt akut nyresvigt samt øgning af serum-kalium. 
As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Luftveje, thorax og mediastinum Ikke almindelig: 
Respiratory, thoracic and mediastinal disorders Uncommon: cough
• kaliumsparende medicin (som visse vanddrivende lægemidler) 
potassium supplements salt substitutes containing potassium potassium-sparing medicines (such as certain diuretics) medicines containing lithium
Den anden side af tabletten er præget med tallet "7465". 
The other side of the tablet debossed with number “7465”.
Irbesartan Teva 150 mg filmovertrukne tabletter EU/1/09/576/014 7 tabletter 
Irbesartan Teva 150 mg film-coated tablets EU/1/09/576/014 7 tablets
Der er set fald i hæmoglobin*, som ikke var klinisk signifikant, hos 1,7 % af de hypertensive patienter med fremskreden diabetisk nyresygdom behandlet med irbesartan. 
In 1.7 % of hypertensive patients with advanced diabetic renal disease treated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.
Den anden side af tabletten er præget med tallet "7464". 
The other side of the tablet debossed with number “7464”.
Hos patienter som ikke er tilstrækkeligt kontrolleret på 150 mg, 1 gang dagligt, kan dosis af irbesartan øges til 300 mg, eller andre antihypertensiva kan tilføjes se pkt. 
In patients insufficiently controlled with 150 mg once daily, the dose of irbesartan can be increased to 300 mg, or other anti-hypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
Sådan skal du tage Irbesartan Teva 
How to take Irbesartan Teva
Irbesartan Teva 75 mg filmovertrukne tabletter EU/1/09/576/001 7 tabletter 
Irbesartan Teva 75 mg film-coated tablets EU/1/09/576/001 7 tablets
Erfaringer med brug af andre lægemidler, der indvirker på renin-angiotensinsystemet, viser at samtidig brug af kalium-besparende diuretika, kaliumtilskud, kaliumholdige salterstatninger eller andre lægemidler, som kan øge serumkaliumniveauet (fx heparin), kan medføre øget serum-kalium. 
Potassium supplements and potassium-sparing diuretics Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Dokumentationen for forbedring af nyresygdom ved brug af irbesartan hos hypertensive type 2-diabetikere er baseret på studier, hvor irbesartan blev brugt efter behov med tillæg af andre antihypertensive lægemidler for at nå det ønskede blodtryk (se pkt. 
The demonstration of renal benefit of irbesartan in hypertensive type 2 diabetic patients is based on studies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).
Indlægsseddel: Information til brugeren Irbesartan Teva 300 mg filmovertrukne tabletter 
Package leaflet: information for the user Irbesartan Teva 300 mg Film-Coated Tablets
Indlægsseddel: Information til brugeren Irbesartan Teva 75 mg filmovertrukne tabletter 
Package leaflet: information for the user Irbesartan Teva 75 mg Film-Coated Tablets
Patienter, der planlægger at blive gravide, bør skifte til anden antihypertensiv behandling, hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA'er skønnes nødvendig. 
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Hvide til offwhite kapselformede filmovertrukne tabletter. 
White to off white capsule shaped, film coated tablet.
Irbesartan 75 mg filmovertrukne tabletter er hvide til offwhite, kapselformede filmovertrukne tabletter. 
Irbesartan 75 mg film-coated tablets are white to off white capsule shaped, film coated tablet.
Indlægsseddel: Information til brugeren Irbesartan Teva 150 mg filmovertrukne tabletter 
Package leaflet: information for the user Irbesartan Teva 150 mg Film-Coated Tablets
Nedsat nyrefunktion, inklusive tilfælde af nyresvigt hos risikopatienter (se pkt. 
Not known: impaired renal function including cases of renal failure in patients at risk (see section 4.4) Reproductive system and breast disorders
Irbesartan 300 mg filmovertrukne tabletter er hvide til offwhite, kapselformede filmovertrukne tabletter. 
Irbesartan 300 mg film-coated tablets are white to off white capsule shaped, film coated tablet.
Hver filmovertrukket tablet indeholder 75 mg irbesartan 
Each film-coated tablet contains 75 mg irbesartan
• Hver Irbesartan Teva 75 mg filmovertrukket tablet indeholder 75 mg irbesartan. 
• Each Irbesartan Teva 75 mg film-coated tablet contains 75 mg irbesartan.
Dosisjustering er ikke nødvendig hos patienter med let/moderat leverfunktionsnedsættelse. 
No dose adjustment is necessary in patients with mild to moderate hepatic impairment.
Hypertensive patienter med type 2 diabetisk nyresygdom 
Hypertension and type 2 diabetes with renal disease
Lægemidler indeholdende aliskiren eller ACE-hæmmere Data fra kliniske studier har vist, at dobbelthæmning af renin-angiotensin-aldosteronsystemet (RAAS) gennem kombinationsbehandling med ACE-hæmmere, angiotensin II-receptorantagonister eller aliskiren er forbundet med en højere hyppighed af bivirkninger som hypotension, hyperkaliæmi og nedsat nyrefunktion (inklusive akut nyresvigt) sammenlignet med brug af et enkelt RAAS-virkende lægemiddel (se pkt. 
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).
Hvis du samtidig tager en en ACE-hæmmer eller aliskiren (se også information under overskrifterne ”Tag ikke Irbesartan Teva” og ”Advarsler og forsigtighedsregler”). 
Your doctor may need to change your dose and/or to take other precautions: If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Irbesartan Teva” and “Warnings and precautions”).
Hver filmovertrukket tablet indeholder 300 mg irbesartan 
Each film-coated tablet contains 300 mg irbesartan
Hud og subkutane væv Ikke kendt: 
hepatitis, abnormal liver function Skin and subcutaneous tissue disorders Not known:
• Hver Irbesartan Teva 300 mg filmovertrukket tablet indeholder 300 mg irbesartan. 
• Each Irbesartan Teva 300 mg film-coated tablet contains 300 mg irbesartan.
• Hver Irbesartan Teva 150 mg filmovertrukket tablet indeholder 150 mg irbesartan. 
• Each Irbesartan Teva 150 mg film-coated tablet contains 150 mg irbesartan.
Irbesartan 150 mg filmovertrukne tabletter er hvide til offwhite, kapselformede filmovertrukne tabletter. 
Irbesartan 150 mg film-coated tablets are white to off white capsule shaped, film coated tablet.
Tag altid Irbesartan Teva nøjagtigt efter lægens anvisning. 
Always take this medicine exactly as your doctor has told you.
Voldsom træthed 
Renal impairment
I ikke-kliniske sikkerhedsstudier forårsagede høje doser af irbesartan (≥ 250 mg/kg/dag hos rotter og 
In non-clinical safety studies, high doses of irbesartan (≥ 250 mg/kg/day in rats and ≥ 100 mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit).
Hver filmovertrukket tablet indeholder 150 mg irbesartan 
Each film-coated tablet contains 150 mg irbesartan
Du skal fortælle det til din læge, hvis du tror du er gravid eller planlægger at blive gravid. 
You must tell your doctor if you think that you are (or might become) pregnant.
Irbesartan Teva 75 mg filmovertrukne tabletter Irbesartan 
Irbesartan Teva 75 mg film-coated tablets Irbesartan
Irbesartan Teva 75 mg filmovertrukne tabletter Hver Irbesartan Teva 75 mg filmovertrukket tablet indeholder 75 mg irbesartan. 
Irbesartan Teva 75 mg film-coated tablets Each film-coated tablet contains 75 mg of irbesartan
Vaskulære sygdomme Almindelig: 
Gastrointestinal disorders Common:
Irbesartan Teva 75 mg filmovertrukne tabletter 
Irbesartan Teva 75 mg film-coated tablets
Ved meget høje doser (≥ 500 mg/kg/dag) inducerede irbesartan degenerative ændringer i nyren hos rotter og makakaber (så som interstitiel nefritis, tubulær udvidelse, 
At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis, tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion.
Irbesartan Teva 300 mg filmovertrukne tabletter Hver Irbesartan Teva 300 mg filmovertrukket tablet indeholder 300 mg irbesartan. 
Irbesartan Teva 300 mg film-coated tablets Each film-coated tablet contains 300 mg of irbesartan
Irbesartan Teva 300 mg filmovertrukne tabletter Irbesartan 
Irbesartan Teva 300 mg film-coated tablets Irbesartan
Irbesartan Teva 150 mg filmovertrukne tabletter Hver Irbesartan Teva 150 mg filmovertrukket tablet indeholder 150 mg irbesartan. 
Irbesartan Teva 150 mg film-coated tablets Each film-coated tablet contains 150 mg of irbesartan
Irbesartan Teva 75 mg filmovertrukne tabletter EU/1/09/576/027 7 tabletter EU/1/09/576/028 14 tabletter EU/1/09/576/029 28 tabletter 
Irbesartan Teva 300 mg film-coated tablets EU/1/09/576/027 7 tablets EU/1/09/576/028 14 tablets
Det skal du vide, før du begynder at tage Irbesartan Teva Sådan skal du tage Irbesartan Teva Bivirkninger 
What Irbesartan Teva is and what it is used for What you need to know before you take Irbesartan Teva How to take Irbesartan Teva Possible side effects
Det er ikke nødvendigt at dosisjustere patienter med nedsat nyrefunktion. 
No dose adjustment is necessary in patients with impaired renal function.
Irbesartan Teva 150 mg filmovertrukne tabletter Irbesartan 
Irbesartan Teva 150 mg film-coated tablets Irbesartan
Irbesartans farmakokinetiske parametre ændres ikke væsentligt hos patienter med mild/moderat cirrose. 
In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
(Det er også bedre at lade være med at tage Irbesartan Teva i begyndelsen af graviditeten - se afsnittet om graviditet). 
if you are more than 3 months pregnant (it is also better to avoid Irbesartan Teva in early pregnancy - see pregnancy section).
Diarré, dyspepsi/halsbrand 
Uncommon: diarrhoea, dyspepsia/heartburn Not known:
Nervesystemet Almindelig: 
hyperkalaemia Nervous system disorders Common:
Irbesartan Teva 150 mg filmovertrukne tabletter 
Irbesartan Teva 150 mg film-coated tablets
Irbesartan Teva 300 mg filmovertrukne tabletter 
Irbesartan Teva 300 mg film-coated tablets
LISTE OVER HJÆLPESTOFFER LÆGEMIDDELFORM OG INDHOLDSMÆNGDE (PAKNINGSSTØRRELSE) 
PHARMACEUTICAL FORM AND CONTENTS
YDERLIGERE OPLYSNINGER Irbesartan Teva indeholder: 
How to store Irbesartan Teva Contents of the pack and other information
Ortostatisk hypotension* 
orthostatic hypotension* Uncommon: flushing
Nyrefunktionsnedsættelse og nyretransplantation Der anbefales periodisk kontrol af serum-kalium- og serum-kreatinin, hvis irbesartan anvendes til patienter med nedsat nyrefunktion. 
When irbesartan is used in patients with impaired renal function, a periodic monitoring of potassium and creatinine serum levels is recommended.
EU/1/09/576/038 50 x 1 tablet (enhedsblister) EU/1/09/576/039 56 x 1 tablet (enhedsblister) EU/1/09/576/042 28 tabletter (kalenderblister) 
EU/1/09/576/038 50 x 1 tablet (unit dose) EU/1/09/576/039 56 x 1 tablet (unit dose) EU/1/09/576/042 28 tablets (calendar pack)
EU/1/09/576/012 50 x 1 tablet (enhedsblister) EU/1/09/576/013 56 x 1 tablet (enhedsblister) EU/1/09/576/040 28 tabletter (kalenderblister) 
EU/1/09/576/012 50 x 1 tablet (unit dose) EU/1/09/576/013 56 x 1 tablet (unit dose) EU/1/09/576/040 28 tablets (calendar pack)
EU/1/09/576/025 50 x 1 tablet (enhedsblister) EU/1/09/576/026 56 x 1 tablet (enhedsblister) EU/1/09/576/041 28 tablets (kalenderblister) 
EU/1/09/576/025 50 x 1 tablet (unit dose) EU/1/09/576/026 56 x 1 tablet (unit dose) EU/1/09/576/041 28 tablets (calendar pack)
Irbesartan Teva anvendes til voksne patienter 
What Irbesartan Teva is and what it is used for
Irbesartan Teva forebygger at angiotensin-II binder sig til disse receptorer. 
Irbesartan Teva prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
• hvis du samtidig tager et af følgende lægemidler til behandling af for højt blodtryk: en ACE-hæmmer (f.eks. enalapril, lisinopril, ramipril), især hvis du har nyrerproblemer i forbindelse med sukkersyge aliskiren 
In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function if you are going to have an operation (surgery) or be given anaesthetics if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems - aliskiren
Vertigo, hovedpine 
Hepatic impairment
Hepatitis, abnorm leverfunktion 
Renal impairment and kidney transplantation
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge til råds, før du tager Irbesartan Teva. 
if you get excessive vomiting or diarrhoea if you suffer from kidney problems if you suffer from heart problems if you receive Irbesartan Teva for diabetic kidney disease.
Unge og voksne 
Adolescents and adults
I kontrollerede kliniske studier blev tegn og symptomer aktivt monitoreret i en opfølgningsperiode på 42 dage. 
In controlled clinical studies, signs and symptoms were actively monitored during a 42-day follow-up period.